By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift - 2Energy agency chief warns of 'black April' for oil supplies
- 3The Extraordinary Excursion of Dental Embed Innovation
- 4Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- 5Misremembering might actually be a sign your memory is working optimally
- Instructions to Clean and Really focus on Your Lab Precious stone
- 'No Kings' protests live updates: More than 8 million turned out across all 50 states, organizers say
- Smooth out Your Funds: Cash The board Simplified
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- NASA set for first crewed moon return in over half a century
- Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- Here are 10 stores where you can get a free Thanksgiving turkey
- The Best Internet based Retailers for Style and Frill
- Dominating the Art of Composing: Creator Bits of knowledge
